Bio-Techne Corp
NASDAQ:TECH

Watchlist Manager
Bio-Techne Corp Logo
Bio-Techne Corp
NASDAQ:TECH
Watchlist
Price: 57.83 USD 0.68% Market Closed
Market Cap: 9B USD

Bio-Techne Corp
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Bio-Techne Corp
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
Bio-Techne Corp
NASDAQ:TECH
Free Cash Flow
$224.1m
CAGR 3-Years
-8%
CAGR 5-Years
5%
CAGR 10-Years
7%
Thermo Fisher Scientific Inc
NYSE:TMO
Free Cash Flow
$6.1B
CAGR 3-Years
3%
CAGR 5-Years
1%
CAGR 10-Years
11%
Danaher Corp
NYSE:DHR
Free Cash Flow
$5B
CAGR 3-Years
-11%
CAGR 5-Years
2%
CAGR 10-Years
4%
Mettler-Toledo International Inc
NYSE:MTD
Free Cash Flow
$889.5m
CAGR 3-Years
10%
CAGR 5-Years
8%
CAGR 10-Years
10%
Agilent Technologies Inc
NYSE:A
Free Cash Flow
$1.1B
CAGR 3-Years
2%
CAGR 5-Years
6%
CAGR 10-Years
-1%
IQVIA Holdings Inc
NYSE:IQV
Free Cash Flow
$2.2B
CAGR 3-Years
9%
CAGR 5-Years
13%
CAGR 10-Years
17%
No Stocks Found

Bio-Techne Corp
Glance View

Bio-Techne Corp. began its journey with a clear focus: to bridge the gap between biological research and practical applications, a mission that it continues to pursue with zeal. At its core, Bio-Techne operates as a pioneer in the production and distribution of biotechnology products, catering to the needs of the scientific community across the globe. The company specializes in providing essential tools for life sciences research, including proteins, antibodies, and reagents, empowering researchers to explore and innovate in fields ranging from cancer biology to neuroscience. These offerings are developed with meticulous care and a deep understanding of the scientific process, which positions Bio-Techne as a trusted ally to laboratories and research institutions worldwide. The financial heartbeat of Bio-Techne lies in its diverse portfolio, which extends into clinical diagnostics and genomics, segments that are critical in an era of personalized medicine and rapid technological advancement in healthcare. The company's revenue streams are robust, driven by a strategic blend of direct sales and collaborations with major pharmaceutical and biotech companies. Furthermore, Bio-Techne smartly leverages its acquisitions to fortify its market position, enhancing its capabilities and expanding its product lines. This agility and foresight not only enable Bio-Techne to sustain its growth trajectory but also to continually meet the ever-evolving demands of a fast-paced, innovation-driven industry.

TECH Intrinsic Value
HIDDEN
Show

See Also

What is Bio-Techne Corp's Free Cash Flow?
Free Cash Flow
224.1m USD

Based on the financial report for Sep 30, 2025, Bio-Techne Corp's Free Cash Flow amounts to 224.1m USD.

What is Bio-Techne Corp's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
7%

Over the last year, the Free Cash Flow growth was -9%. The average annual Free Cash Flow growth rates for Bio-Techne Corp have been -8% over the past three years , 5% over the past five years , and 7% over the past ten years .

Back to Top